Perceptive Advisors Discloses 7.6% Stake in Immatics After $7.5M Offering Purchase
IMTX sits 86% above its 52-week low of $5.05.
Summary
Perceptive Advisors disclosed a 7.6% stake in Immatics after buying 863,060 shares in the company's recent $150 million offering, signaling institutional conviction in the cancer immunotherapy developer.
Key Events · Ownership and Investor Activity · IMTX
-
Perceptive Buys $7.5M in Offering
Perceptive Life Sciences Master Fund purchased 863,060 shares at $8.69 per share on August 26, 2026, in Immatics' underwritten offering.
-
Stake Reaches 7.6%
Perceptive Advisors and affiliates now hold 11,418,016 shares, representing 7.6% of Immatics' outstanding ordinary shares.
-
Board-Level Alignment
Adam Stone, Perceptive's CIO, holds options for 219,500 shares (171,500 exercisable) tied to his board service, with compensation offset through management fees.
-
Offering Context
The purchase follows Immatics' $150 million underwritten offering that closed August 26, netting $161.1 million after full exercise of the underwriters' option.
Analysis · IMTX · Life Sciences
A prominent life sciences investment firm, Perceptive Advisors, purchased 863,060 shares at $8.69 per share in Immatics' recently closed $150 million underwritten offering. The purchase brings Perceptive's total stake to 11.4 million shares, or 7.6% of the company. This is a meaningful vote of confidence from a sophisticated biotech investor, especially coming just days after the offering priced. The $8.69 purchase price is below today's $9.38 price, but that reflects the offering's pricing mechanics rather than a discount signal. Perceptive's CIO Adam Stone also holds board-level stock options, reinforcing the firm's long-term alignment with Immatics.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMTX was trading at $9.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.05 to $12.41. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.